# Small Molecules of the Month

November 2021
drughunter.com




## PF-07321332 | SARS-CoV-2 $M^{pro}$

**oral pan-coronavirus antiviral, rev. covalent**
**Ph. III candidate for COVID-19 (300 mg BID)**
**from SARS-CoV-1 inhibitor (WO2005113580)**
**Science**
**Pfizer Worldwide Research**



## GS-621763 | SARS-CoV-2

**oral antiviral prodrug of remdesivir**
**effective in a ferret SARS-CoV-2 model**
**from remdesivir nucleoside (GS-441524)**
**Nature Communications**
**Gilead Sciences Inc.**



## ASP2453 | $KRAS^{G12C}$

**oral drug, covalent inhibitor of $KRAS^{G12C}$**
**effective in $KRAS^{G12C}$-mutated cancer models**
**SBDD utilizing KRAS proto-oncogene, GTPase**
**British Journal of Cancer**
**Astellas Pharma Inc.**



## SY-5609 | CDK7

**oral picomolar & reversible CDK7 inhibitor**
**Ph. I candidate in breast cancer comb. therapy**
**from previous CDK7 inhibitor SY-1365**
**Journal of Medicinal Chemistry**
**Syros Pharmaceuticals Inc.**




## BIIB091 | BTK

**oral reversible BTK kinase inhibitor**
**Ph. I candidate for multiple sclerosis**
**from prior BTK inhibitor BIIB0685**
**Journal of Medicinal Chemistry**
**Biogen**



## compound Ia | BRAF

**oral BRAF inhibitor, brain penetrant**
**effective in A375-derived mouse models**
**from prior paradox inducing BRAF inhibitors**
**Clinical Cancer Research**
**Roche**



## DS96432529 | CDK8

**oral CDK8 kinase inhibitor**
**effective in ovariectomized rat model**
**CDK8 identified as MoA after screen**
**Bioorganic & Medicinal Chemistry Letters**
**Daiichi Sankyo Co. Ltd.**



## compound 27 | ELOVL1

**oral ELOVL1 inhibitor for ALD, CNS penetrant**
**toxicities observed in higher species**
**internal HTS and LBDD**
**Journal of Medicinal Chemistry**
**Vertex Pharmaceuticals Inc.**




## tepotinib | MET

**oral MET kinase inhibitor**
**approved for clinical use in NSCLC**
**internal HTS and SBDD**
**Clinical Cancer Research**
**Merck KGaA**




## PF-06939999 | PRMT5

**oral SAM-competitive PRMT5 inhibitor**
**Ph. I candidate for solid tumors (adv. or met.)**
**SBDD utilizing PRMT5:MEP50 w/ A9145C**
**Molecular Cancer Therapy**
**Pfizer Oncology**




## compound 5 | VPS34

**oral selective VPS34 kinase inhibitor**
**discontinued due to potential toxicity**
**SBDD and SAR optimization**
**Journal of Medicinal Chemistry**
**Genentech Inc.**




## compound 59 | TRPM8

**TRPM8 blocker for ocular administration**
**effective w/ ocular admin. in animal model**
**cell-based screen. and opt. of thiazoles series**
**Journal of Medicinal Chemistry**
**Dompé Farmaceutici S.p.A**



## M5717 | PfeEF2

**oral plasmodium eEF2 inhibitor**
**Ph. I candidate for malaria treatment**
**from phenotypic screen & optimization**
**The Lancet**
**Merck Institute for Pharmacometrics**




## compound 1 | RET

**oral RET kinase inhibitor**
**effective in tumor xenograft model**
**from scaffold hopping & optimization**
**ACS Medicinal Chemistry Letters**
**Novartis Genomics Institute**

## HIGHLIGHTS FROM DRUG DISCOVERY ARTICLES PUBLISHED ONLINE | NOV. 2021

drug hunter